Acquiring Company
Lakefront Biotherapeutics NV
Acquired Company
Ouro Medicines
San FranciscoBiotechnologyHealth CareTherapeuticsBiotechnologyHealth CareTherapeuticsDescription
Lakefront Biotherapeutics has completed the acquisition of Ouro Medicines in collaboration with Gilead Sciences. This strategic move aims to advance the development of gamgertamig, a promising T-cell engager for autoimmune diseases. The companies expect to enter registrational studies for gamgertamig in 2027. This acquisition enhances Lakefront's position in innovative immunotherapy treatments.
Related People
M&A Insights
Based on deal dataFrequently asked
Who acquired Ouro Medicines?
Ouro Medicines was acquired by Lakefront Biotherapeutics NV. The deal was reported on August 10, 2026. Lakefront Biotherapeutics is a biotechnology company focused on developing innovative immunotherapy treatments. They leverage unique technologies to create potential first-in-class therapies for autoimmune diseases. Lakefront Biotherapeutics NV is publicly traded (LKFT) and operates in Biotechnology.
When did Lakefront Biotherapeutics NV acquire Ouro Medicines?
Lakefront Biotherapeutics NV's acquisition of Ouro Medicines was reported on August 10, 2026. Lakefront Biotherapeutics has completed the acquisition of Ouro Medicines in collaboration with Gilead Sciences. This strategic move aims to advance the development of gamgertamig, a promising T-cell engager for autoimmune diseases. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does Ouro Medicines do?
Ouro Medicines is a biotechnology company focused on developing immune reset therapeutics for chronic immune-mediated diseases. It is privately held, operating in Biotechnology, and is based in San Francisco.